Omeros Corporation (Nasdaq: OMER) today announced that interim analysis data from its ongoing Phase 2 study of OMS906 in ...

Sobi® today announced that the European Commission (EC) has approved an indication extension for Aspaveli® (pegcetacoplan) for treatment ...

One of the rarest of rare blood cancers, Erdheim-Chester disease presents diagnosis and treatment challenges. Erdheim-Chester disease is a rare blood cancer that manifests itself in a variety of ways, ...

Despite readily available treatments for paroxysmal nocturnal hemoglobinuria, only around one-quarter of patients with the condition receive treatments.

A retrospective analysis suggested that immune cells play a role in the progression of paroxysmal nocturnal hemoglobinuria ...

Chronic hemolytic anemia is a common manifestation of PNH but nocturnal hemoglobinuria is rare. The disorder may lead to renal insufficiency, thrombosis, or pulmonary hypertension and is ...

RLYB-116 is under clinical development by Rallybio and currently in Phase I for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase I drugs for Paroxysmal Nocturnal Hemoglobinuria have ...

RLYB-116 is under development for the treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis and other dermatological diseases. It is administered through subcutaneous route. RLYB-116 is ...

Expert Rev Gastroenterol Hepatol. 2012;6(6):731-744. Myeloproliferative disorders (MPD) deserve specific mention due to their high frequency in BCS. MPD result in excess cell production by the ...

CLEVELAND, OHIO, UNITED STATES, April 15, 2024 /EINPresswire.com/ -- NovelMed today announced that the Food and Drug Administration (FDA) has granted Orphan Drug ...